The role of VEGF-A165b in trophoblast survival

Victoria L Bills1,2, Maryam Hamdollah-Zadeh1, Peter W Soothill2, Steven J Harper1 and David O Bates3*

Abstract

Background: Pre-eclampsia remains a dominant cause of maternal and fetal mortality in developed countries. In a previous prospective study we identified a fall in the VEGF-A isoform VEGF-A165b in the plasma of patients in the first trimester to be a predictor of later pre-eclampsia. VEGF-A165b has been shown to have potent cytoprotective properties in many cell types. We therefore tested the hypothesis that VEGF-A165b may be cytoprotective for placental trophoblasts.

Methods: We used an immortalised first trimester trophoblast cell line exposed to chemical toxicity, and physiological (<2% O2) and atmospheric oxygen (21% O2) in the presence or absence of VEGF-A165b, angiogenic VEGF-A165a, a non-specific anti-VEGF-A blocking antibody (bevacizumab), or a specific anti-VEGF-A165b antibody. Cell viability and cytotoxicity were measured by trypan blue and LDH assay respectively.

Results: Under high (21%) levels of oxygen, trophoblast viability was increased, and cytotoxicity reduced by exogenous recombinant VEGF-A165b (p < 0.05, n = 10) or VEGF-A165a. The cytoprotective effect was not seen under lower (<2%) oxygen conditions, where VEGF-A165b was upregulated. However inhibition of VEGF-A with blocking antibodies (bevacizumab or anti-VEGF-A165b) had marked cytotoxic effects under low oxygen conditions presumably through the blockade of autocrine survival pathways.

Conclusions: These results show that when trophoblasts are exposed to lower oxygen tensions (as they are early in the 1st trimester) endogenous VEGF-A165b contributes to their survival through an autocrine pathway. In contrast in high oxygen conditions exogenous VEGF-A isoforms have a greater effect on trophoblast survival.

Keywords: VEGF, Pre-eclampsia, Trophoblasts

Background

Abnormal placental development is central to the pathogenesis of pre-eclampsia. The early placenta is made up of microvilli consisting of a mesenchymal core surrounded by cytotrophoblast stem cells that develop into either overlying syncytiotrophoblasts, or extravillous trophoblasts, which grow out from the placenta. The partial pressure of oxygen in the normal first trimester placenta has been found to be lower than 20 mmHg [1], i.e. the trophoblasts are physiologically used to a lower oxygen tension than later in pregnancy. At 10–12 weeks of gestation, trophoblast plugs loosen and oxygenated maternal blood enters the intervillous space, raising the oxygen tension [2]. This stimulates trophoblasts to differentiate into an invasive phenotype, which are less proliferative and more susceptible to apoptosis [3]. These processes are regulated by a wide variety of molecules, including hypoxia-inducible factor-1α (HIF-1α), VEGF and transforming growth factor-β [4,5].

VEGF-A isoforms play critical roles in the development of the placenta. In the first trimester placenta VEGF-A is present in the cytotrophoblast, syncytiotrophoblast and endothelial cells in the villi [6]. Isoforms of VEGF-A exist in two distinct families, formed by alternative mRNA splicing [7]. The canonical isoforms are generated by splicing of pre-mRNA into the proximal splice site in exon 8a, after alternative splicing of exons 6 and 7, resulting in a family of isoforms with angiogenic activity, termed VEGF-Axxx where xxx refers to the number of amino acids in the protein (e.g. VEGF-A165, VEGF-A121). The most widely studied isoform, VEGF-A165 has pro-angiogenic, pro-permeable and vasodilatory properties [8]. Alternative splicing in exon 8, 66 bases downstream in the pre-mRNA results in a family of isoforms, termed VEGF-Axxx-b, which differ in their final six
C-terminal amino acids. Thus VEGF-A165b, VEGF-A121b and VEGF-A189b can be generated as sister isoforms of the canonical isoforms [9]. VEGF-A165b and VEGF-A121b are anti-angiogenic in vivo. VEGF-A165b, the most extensively studied isoform, binds to and activates VEGF-R2, but is quantitatively and qualitatively different from VEGF-A165a [10], stimulating cyto-protective signalling, but not angiogenic pathways [11,12]. In terms of cell survival therefore, VEGF-A165a and VEGF-A165b often have the same rather than contrasting properties. Although evidence is mounting for the expression and role of VEGF-A165a in placental tissue, little is known about the expression and function of placental VEGF-A165b, in particular the effect of this alternatively spliced anti-angiogenic isoform on trophoblast survival. This is in contrast to the recent demonstration of the anti-angiogenic role of VEGF-A165b in skin in patients with systemic sclerosis [13].

The foundations of pre-eclampsia are laid down in the first trimester, with inadequate invasion of placental trophoblasts into the maternal uterine spiral arteries. In the first trimester, women who were later to develop pre-eclampsia had lower levels of plasma VEGF-A165b than pregnant women who remained normotensive throughout pregnancy [14]. The finding that VEGF-A165b is cyto-protective for some cell types, led us to test the hypothesis that VEGF-A165b may contribute to trophoblast survival at a crucial time in the first trimester and deficiency of the molecule may prevent trophoblast well-being and the successful physiological process of spiral artery remodelling by trophoblast cells.

**Methods**

**Cell culture**

Cell viability and cytotoxicity assays were performed on HTR-8/SVneo cells, a human trophoblast cell line immortalised using SV40 (Simian Virus 40) large T antigen (Tag), a kind gift from Charles H. Graham, University of Toronto, who first established this cell line [15]. These cells can proliferate indefinitely, and have been shown to retain many of their phenotypic features of the non-transfected parent trophoblast cells such as staining for cytokeratin [16]. They are however, a transformed cell line, rather than a primary trophoblast culture.

These cells were cultured in sterile filtered RPMI 1640 media supplemented with 5% fetal bovine serum and 1% penicillin/streptomycin (RPMI/5%FBS/1%PS). Cells were incubated in atmospheric oxygen conditions (5% CO2 and 21% O2) at 37°C in T25 flasks, starting at passage 78 and split twice weekly. HTR8/SVneo cells were cultured in RPMI/5%FBS/1%PS for at least 2 weeks to super-confluency, and formed the villous trophoblast cell columns that characterise this cell type.

**Cytoprotection assay**

HTR-8/SVneo cells were plated onto 6-well cell culture plates at a density of 1x10^4 with 2 ml RPMI/5%FBS/1%PS and incubated at 37°C in 21% O2. After 24 hours the cells were rinsed in 2 ml 1xPBS and the media replaced with serum free RPMI 1640 supplemented with or without VEGF-A165b 40 ng/ml. After 48 hours of incubation at 37°C media was harvested and centrifuged at 3000 rpm for 3 minutes. The resulting pellets consisted of dead HTR-8/SVneo cells, which were resuspended in 1 ml of RPMI. The remaining live cells on the surface of the wells were removed by trypsinisation (1 ml trypsin solution per well), and 2 ml RPMI added to inactivate the trypsin. Following centrifugation of the contents of the well at 3000 rpm for 3 minutes, the supernatant was removed and the pellet of live cells was resuspended in the dead cell solution to mix both live and dead cells together. The solution was pipetted thoroughly and 100 μl was transferred to an eppendorf containing 100 μl of 0.4% Trypan blue (400 mg trypsin blue in 100 ml 1xPBS). Trypan blue dye is able to pass through the cell membrane of dead, but not live cells. The % viability of cells after treatment with agents was calculated as:

\[
\frac{100 \times \text{Live Cells}}{\text{Dead Cells} + \text{Live Cells}}
\]

**Lactate Dehydrogenase (LDH) assay for cytotoxicity**

The LDH assay (CytoTox 96, Promega) was carried out according to manufacturer’s instructions. Cells grown to 90-95% confluency were seeded onto 96-well sterile cell culture plates at a density of 3 x 10^4 cells per well and 100 μl RPMI/5%FBS/1%PS was added to each well before incubation at 37°C. After 24 hours the media was removed, and cells were washed with 1 x PBS once before fresh serum free media was added (100 μl/well). The following treatments were added to the wells: 1nM or 2nM of rhVEGF-A165 or VEGF-A165b, an antibody against VEGF-A bevacizumab (25nM), or a VEGF-A165b antibody: clone 56-1 (R&D systems MAB3045), at 25 or 50 nM. Control wells contained serum free media only and the positive control wells contained 5 mM sodium butyrate, a known cytotoxicity inducing agent. No IgG control was included. Plates were incubated in 21%O2 at 37°C. After 48 hours media (50 μl/well) was collected from wells and transferred to fresh 96-well plates for the later quantification of LDH concentration in the media after 48 hours of treatment. The original culture plates with their 50 μl/well of remaining media was then freeze-thawed at −80°C and then 50°C to lyse the HTR-8/SVneo cells. The resulting cell lysates were collected and transferred onto fresh 96-well plates (lysat) and both media and lysate plates were centrifuged at 1500 rpm for 10 minutes. 50 μl/well of solution in each well on both sets
of plates were transferred to two new sets of plates to which the detection substrate tetrazolium salt was added for 30 minutes. Visible wavelength absorbance data were measured in a plate reader. The % cytotoxicity was calculated as:

\[
100 \times \frac{OD_{\text{media}}}{(OD_{\text{media}} + OD_{\text{lysate}})}
\]

LDH assays were repeated in triplicate and performed in physiological (<2% O₂) as well as atmospheric (21% O₂) conditions.

ELISA
Cells were lysed using RIPA lysis buffer containing protease inhibitors and the protein concentration was measured using Precision Red (Cytoskeleton, Inc), according to the manufacturer's guidelines. Pan-VEGF and VEGFxxxb ELISA was performed using the VEGF DuoSet ELISA kit DY293 and DY3045, respectively (R&D Systems, Abingdon, UK). This VEGF-Axxxb ELISA should detect all the VEGF-Axxxb isoforms, but not the VEGF-Axxx isoforms, but that the affinity of the antibodies to the 'minor' isoforms such as VEGF-A121b and VEGF-A189b has not been determined. Briefly, 1 μg/ml goat anti-human pan-VEGF or 2 μg/ml anti-human VEGFxxxb (Clone 56/1) were used as capture antibodies, overnight at room temperature (RT). After washing and blocking steps, serial dilutions of, rhVEGF165 or rhVEGF165b standards were added to each well in triplicate, at concentrations ranging from 15.625 pg/ml to 4 ng/ml. Sample lysates were typically diluted 1:5 in blocking solution and added in duplicate to each well. Either biotintated goat anti-human VEGF (0.1 μg/ml), or mouse anti-human VEGFxxxb (0.25 μg/ml), was used as detection antibody. Absorbance was read in a plate reader Opsys MR 96-well plate reader (Dynex Technologies, Chantilly, VA, USA) at 450 nm, with the control reading at 570 nm. Revelation Quicklink 4.25 software was also used to construct a standard curve from mean absorbance values of standards enabling the estimation of VEGF concentration for each sample.

Statistics
Comparisons between VEGF-A165b treated (test) trophoblast cells were made with the serum free media (control) trophoblast cells. Statistical analyses of cell culture data were made using Unpaired t tests and one way ANOVAs, with p < 0.05 regarded as significant. Values are expressed as means ± S.E.M.

Results
VEGF-A165b is cytoprotective for trophoblasts
To determine whether exogenous VEGF-A165b was cytoprotective for placental trophoblasts, 1 × 10⁵ HTR-8/SVneo trophoblast cells were cultured in serum free medium (SFM) ± 1nM VEGF-A165b for 48 hours in atmospheric oxygen (n = 10). Viability of cells exposed to VEGF-A165b, measured by trypan blue exclusion, was increased by 21% compared to control conditions (viability 75% ± 2.8 vs. 54% ± 8.1, Unpaired t test, p < 0.05, n = 10, Figure 1A). The LDH assay was then used to determine if VEGF-A165b increases trophoblast survival in a dose dependent manner. 19 wells were treated for 48 hours with SFM, SFM + 1nM VEGF-A165b or 2nM VEGF-A165b in 21% O₂. A dose dependent decrease in cytotoxicity occurred (% cytotoxicity 33.6% ± 0.6, 29.2% ± 0.9, and 24.2% ± 3.5 respectively, One way ANOVA, p = 0.0019, Dunnett’s Multiple Comparison Test, Figure 1B). This was similar to that induced by VEGF-A165a – cytotoxicity decreased from 26.5 ± 2.4% in SFM to 20.7 ± 3.3% when cultured in 2nM VEGF-A165a (Unpaired t test, p < 0.05, n = 13, Figure 1C). To determine whether VEGF-A165b could prevent chemically induced cytotoxicity, 3 × 10⁴ trophoblast cells were cultured with 5 mM sodium butyrate ± 1nM VEGF-A165b. Pre-incubation of the cells with 1nM VEGF-A165b for two days significantly decreased Na butyrate- induced cell death (cytotoxicity 58% ± 2.7 vs. 39% ± 3.2, Unpaired t test, p < 0.05, n = 8, Figure 1D).

Lower oxygen tensions abolish the effect of exogenous VEGF-A on trophoblast survival
In the early placental environment, before 10 weeks of gestation, trophoblasts experience lower oxygen tensions of less than 20 mmHg (2.5%) [1] and VEGF-A expression has been shown to be induced by such low oxygen tensions [18]. We therefore determined whether low oxygen tension itself was cytoprotective by inducing VEGF-A expression. Immortalised HTR-8/SVneo first trimester trophoblast cells were cultured for 48 hours in serum free media (SFM) 21% O₂ or <2% O₂ conditions. The LDH assay was used to determine cell cytotoxicity. After 48 hours, cytotoxicity was reduced in the cells exposed to lower oxygen conditions (17.8% ± 2.6) compared to cells exposed to atmospheric oxygen (33.7% ± 0.63, n = 16, Unpaired t test, p < 0.0001, Figure 2A).
Figure 1 Exogenous VEGF-A is cytoprotective for trophoblasts in atmospheric oxygen conditions. 

A. HTR-8/SVneo (first trimester immortalised trophoblast) cells were cultured for 48 hours in SFM ± 1nM VEGF-A\textsubscript{165b} and survival assessed by Trypan exclusion. (* = p < 0.05, Unpaired t test, n = 10).
B. Cytotoxicity assessed by LDH release (n = 19, One way ANOVA, p = 0.0019, Dunnett’s Multiple Comparison Test).
C. Trophoblasts were cultured in SFM ± 2nM VEGF-A\textsubscript{165a} in 21% O\textsubscript{2}. After 48 hours cytotoxicity determined by LDH assay. (Unpaired t test, p < 0.05, n = 13).
D. In the presence of 5 mM sodium butyrate (NaBu, a cytotoxic agent), addition of 1 nM VEGF-A\textsubscript{165b} significantly decreased the trophoblasts cytotoxicity (p < 0.05, Unpaired t test, n = 8).

Figure 2 First trimester trophoblast cells are resistant to low oxygen tensions. 

A. Trophoblasts were cultured in 21% O\textsubscript{2} or with reduced oxygen (<2% O\textsubscript{2}) conditions for 48 hours in serum free media (SFM) and cytotoxicity assessed by LDH release (Unpaired t test, p < 0.0001, n = 16).
B. Trophoblasts were cultured for 48 hours in SFM or 2nM VEGF-A\textsubscript{165b} in <2% O\textsubscript{2} and cytotoxicity assessed by LDH release (Unpaired t test p = 0.13, n = 13).
C. Trophoblasts cytotoxicity assessed by LDH release in cells treated with 2nM VEGF-A\textsubscript{165a} under lower oxygen conditions.
D. Trophoblasts were cultured for 48 hours in low or atmospheric oxygen conditions. ELISA showed that VEGF-A\textsubscript{165b} expression was increased by lowering pO\textsubscript{2} (1812 pg/ml ±33 vs. 1407 pg/ml ±95, Unpaired t test, p = 0.016).
To determine whether VEGF-A$_{165b}$ could further protect cells in lower oxygen conditions, HTR-8/SVneo cells were treated with 1nM VEGF-A$_{165b}$ in SFM for 48 hours in <2% O$_2$. This had no effect on cytotoxicity. To ensure that this was not due to an altered responsiveness of the cells, a separate set of cells were treated with or without 2 nM VEGF-A$_{165a}$, which also had no effect on cytotoxicity (n = 21, Unpaired t tests, p = 0.2 Figure 2B). To determine whether VEGF-A$_{165a}$ was able to reduce cytotoxicity, cells were treated with 2nM VEGF-A$_{165a}$ in <2%O$_2$. Again no reduction in cytotoxicity was seen (Figure 2C). This suggested that either the cells were no longer able to respond to VEGF-A, that they had already reached a maximal reduction in cytotoxicity, or that the cells were producing endogenous VEGF-A, and that this was acting sufficiently in an autocrine manner. We therefore measured VEGF-A$_{165b}$ levels in 1 × 10$^5$ HTR8/SVneo cells incubated in either <2% O$_2$ or atmospheric oxygen. After 48 hours, cells were harvested, protein extracted and expression of VEGF-A$_{165b}$ in cell lysate measured by ELISA. VEGF-A$_{165b}$ from low oxygen treated trophoblasts was significantly increased compared to cell lysate from trophoblasts cultured in 21% O$_2$, when measured by ELISA (1.8 ± 0.033 ng/ml vs. 1.4 ± 0.095 ng/ml respectively, Unpaired t test, p = 0.016, Figure 2D).

In low oxygen conditions, inhibition of total VEGF-A via Bevacizumab, or exclusively VEGF-A$_{165b}$ increases cytotoxicity

If endogenous VEGF-A is responsible for the reduction in cytotoxicity under low oxygen conditions, then inhibition of endogenous VEGF-A should be cytotoxic. In a series of 20 experiments, 3 × 10$^4$ HTR-8/SVneo cells were cultured in SFM ± 25nM Bevacizumab (to inhibit all VEGF-A isoforms), or 25nM of an anti-VEGF-A$_{165b}$ monoclonal antibody (clone 56–1), to inhibit VEGF-A$_{165b}$ only, leaving VEGF-A$_{165a}$ active. Following incubation for 48 hours in a hypoxia chamber (<2% O$_2$), an LDH assay was performed and cytotoxicity was expressed as relative LDH concentration in the media compared to lysate. Baseline cytotoxicity in SFM was 17.8 ± 2.6%. When cultured in Bevacizumab, cytotoxicity rose to 26.4 ± 1.6%, and was even higher when exposed to clone 56–1, 30.8 ± 2.7% (One Way ANOVA, p = 0.0068, Dunnett’s Multiple Comparison’s Test, Figure 3A). To determine whether this cytotoxicity was oxygen dependent, 3 × 10$^4$ HTR-8/SVneo

![Figure 3](http://www.biomedcentral.com/1471-2393/14/278)
cells were cultured in the presence of SFM ± 25 nM Bevacizumab or 50 nM anti-VEGF-A165b in 21% O2. After 48 hours, the media and cell lysate were harvested for the quantification of LDH, and cytotoxicity was calculated. There was no significant difference in cell death following exposure to the anti-VEGF-A165b antibody compared to control conditions (Unpaired t Test, p = 0.6, n = 14), and a small but not statistically significant increase following exposure to Bevacizumab for 48 hours (31.4 ± 1.8% vs. 27.6 ± 0.8%, Unpaired t test, p = 0.0599, n = 49, unpaired t test with Welch correction for unequal variance, F test to compare variances p = 0.0009, Figure 3B&C).

Discussion

We show here that trophoblasts thrive in low oxygen conditions partly by inducing VEGF-A expression resulting in an autocrine cytoprotective mechanism that is specific for the anti-angiogenic isoforms such as VEGF-A165b. In early placentation, extravillous trophoblasts differentiate from a proliferative to an invasive phenotype [19]. As these extravillous trophoblasts invade the maternal blood vessels they form plugs; groups of cells that occlude the spiral arteries and prevent oxygenated maternal blood from entering the intervillous space while the spiral arteries remodel to generate low resistance vessels that will provide maternal blood to the placenta [20]. Up to 10 weeks of gestation, the trophoblast cells therefore exist in a lower oxygen environment, and this results in the trophoblasts maintaining a proliferative, non-invasive phenotype [21]. Thus, the results presented here provide a potential cellular mechanism through which the trophoblasts in normal pregnancy could survive the low oxygen levels induced by their plugging of the spiral arteries.

If this upregulation of VEGF-A165b does not occur then the trophoblasts will suffer more cell death. In normal placental tissue, tightly regulated processes of proliferation and cell death occur continuously. Cell death may be apoptotic (programmed cell death, where organelles are packaged up to be phagocytosed), or necrotic, which involves the cytoplasm and organelles being shed into the extracellular matrix without any expenditure of cellular energy [22]. In pre-eclampsia, trophoblasts undergo increased rates of apoptosis [23,24], and pre-eclamptic trophoblasts are more susceptible to stressful events such as TNF-α exposure, which induces apoptosis [25]. It is known that certain growth factors such as epidermal growth factor (EGF) can rescue trophoblasts from apoptosis [26]. Furthermore, in 2002 Smith et al. showed that insulin-like growth factor-1 (IGF-1), basic fibroblast growth factor (bFGF), and platelet derived growth factor AA (PDGF-AA) were also able to partially inhibit apoptosis induced by TNF-α and IFN-β, although VEGF-A165 was not able to do so [27]. The data presented here shows for the first time that the anti-angiogenic but cyto-protective isoform VEGF-A165b can act as a survival factor, as it rescued trophoblasts from sodium butyrate induced cell death. They also suggest that a lack of VEGF-A165b expression early in pregnancy, as is seen in women that go onto develop pre-eclampsia, might result in increased cell death, and hence contribute to the development of pre-eclampsia.

The expression of the pro-angiogenic factors VEGF-A and PI GF has been demonstrated in first trimester human trophoblast and placentae [17,28]. Those authors showed that during low oxygen conditions (corresponding to before 10 weeks of gestation) the expression of VEGF-A was significantly up-regulated by 8-fold in comparison to atmospheric conditions, while PI GF expression was reduced under low oxygen tensions. However, they did not use probes or antibodies that would distinguish between the pro-angiogenic isoforms (VEGF-A121a, VEGF-A165b, VEGF-A189b) or the anti-angiogenic isoforms (VEGF-A121b, VEGF-A165b, or VEGF-A189b).

The mechanism of action of VEGF-A165b on cytoprotection is still not yet clear. The expression of all three VEGF-A receptors (VEGFR1 or Flt-1, VEGFR2 or KDR, and VEGFR3) has been demonstrated in trophoblast cells [28,29]. VEGF-A165b exerts its effects through VEGFR-2, whereas VEGF-A165b has been shown to act by preventing VEGF-A165b acting on VEGFR2 and by acting directly on VEGFR1 in podocyte epithelial cells and endothelial cells. Recently, VEGF-A165b has been shown to act as a cytoprotective agent on retinal pigmented epithelial cells and neurons through VEGFR2 but its mechanism of action on trophoblast survival is not yet known.

This work shows that VEGF-A165b addition to cultured trophoblasts in high oxygen conditions reduces cytotoxicity, and although addition of VEGF-A165b to cells under low oxygen conditions does not increase survival, specific inhibition of the VEGF-A165b isoform increases trophoblast death, suggesting that VEGF-A165b is a trophoblast survival factor both when administered exogenously in conditions of high pO2, and via an autocrine pathway during low pO2. The measured increase in VEGF-A165b during low pO2 was relatively small (30%), but it is difficult to extrapolate from this to the local concentration at the cell membrane. This work also shows that low pO2 increases the expression of VEGF-A165b by trophoblast cells in culture, suggesting that exogenous VEGF-A165b does not reduce cell death under low pO2 because endogenous VEGF-A165b, present in abundance, is already fulfilling the survival role. However, because the anti-VEGF-A165b antibody inhibits endogenous VEGF-A165b, a resulting increase in trophoblast cytotoxicity was observed. It is therefore likely that under low pO2 conditions VEGF-A165b isoforms play the more important role in trophoblast survival, and the finding that low pO2 stimulates the
expression of VEGF-A165b supports this hypothesis. However, although total VEGF-A inhibition and specific inhibition of VEGF-A165b had similar effects, this does not rule out an overlapping role for VEGF-A165a. In addition, this work demonstrates reduced trophoblast death in low pO2, and increased cytotoxicity with VEGF-A165b inhibition. Therefore, the reduction of VEGF-A165b at 12 weeks of gestation seen in the plasma of women who will later develop pre-eclampsia may be reflecting an (as yet) unidentified pathological process in the trophoblasts, which prevents trophoblasts from producing sufficient VEGF-A165b, which if secreted in adequate amounts would help to promote trophoblast survival, and these increased levels would be reflected in the plasma. Thus under normal pregnancy conditions, the trophoblast survival in the uterine spiral artery plugs enables the appropriate remodelling of the artery to a low resistance vessel capable of providing sufficient maternal blood to the placenta. If the trophoblasts do not produce sufficient VEGF-A165b then they would undergo apoptosis in the low oxygen conditions of the first trimester, and the plug would be unsustainable, and hence not allow the arteries to undergo appropriate remodelling.

The above hypothesis makes a number of assumptions that should be made clear. First, the oxygen tension in the trophoblasts in vivo rises from 18 mmHg (2.5%) at 8 weeks to 40 mmHg (5%) at 10 weeks, and then to 90-100 mmHg (11-13%) at later time points. Thus 21% oxygen is hyperoxic for trophoblasts, in vivo. It will therefore be important to determine in a more physiologically relevant model (such as isolated perfused placenta), the effects of increasing oxygen tension on cytotrophoblast survival. Secondly, the effects of low oxygen tension are likely to be complex at tensions lower than 2%. It is possible that very low oxygen levels (e.g. <0.1%) may induce a true “hypoxia” in trophoblasts, and the effect of this on VEGF splicing has not been determined. We were unable to regulate the oxygen levels below 2% due to the sensitivity of the sensor, so it is possible that lower oxygen tensions were seen. Finally, trophoblasts grown in culture are unlikely to behave as they do in vivo, and so the extrapolation of these data to human physiology must by definition be speculative, but these findings provide a rationale for a more in depth investigation using intact placental tissues. Moreover, further work is now necessary to determine whether VEGF-A165b is able to induce the invasive properties of trophoblast cells. In addition, the LDH assay does not differentiate between necrosis and apoptosis. Future experiments using more specific methods such as flow cytometry are required, as this would allow the effect of VEGF-A165b on the entire trophoblast cell cycle to be determined. Moreover, we did not compare bevacizumab or anti-VEGF-A165b antibodies to a control IgG, as the former is a human and the latter a mouse antibody. Previous studies have shown that treatment of trophoblasts with IgG by itself has no effect on trophoblast cell death [30], but further experiments should include this as a control. Finally, these experiments have not yet clarified the relative functional effects of the pro- and anti-angiogenic VEGF-A isoforms on trophoblast proliferation and invasion, including which isoform is the more important depending on the oxygen tension of the environment. Co-culture experiments with decidua and trophoblast, at differing oxygen tensions and exposure to different doses of the two VEGF-A isoforms are now required, as it is not yet possible to make a leap from effects of exogenous and endogenous VEGF in culture to the effects of VEGF isoforms in humans.

**Conclusion**

These experiments have shown that low pO2 increases the production of VEGF-A165b by placental trophoblasts, and that blocking VEGF-A165b under these conditions leads to trophoblast cell death. Therefore VEGF-A165b may be a survival factor for trophoblasts during the first trimester of pregnancy, such that VEGF-A165b deficiency may decrease the ability of trophoblasts to survive and subsequently invade the maternal spiral arteries during the physiological process of spiral artery remodelling. It is well established that inadequate spiral artery remodelling is associated with the development of pre-eclampsia later in the pregnancy. These molecular findings of reduced VEGF-A165b being associated with trophoblast toxicity in the (physiologically) low oxygen levels of first trimester of pregnancy positively corresponds to the previously reported finding that women who eventually develop pre-eclampsia have reduced plasma levels of VEGF-A165b during their first trimesters. These findings may imply a time and anatomical specific VEGF-A165b deficiency in the pathophysiology of pre-eclampsia.

**Abbreviations**

ANOVA: Analysis of variance; bFGF: Basic fibroblast growth factor; BOC: British Oxygen Company; EGF: Epidermal growth factor; ELISA: Enzyme linked immunosorbent assay; FBS: Fetal bovine serum; Flt-1: fms-like tyrosine kinase; HIF: Hypoxia inducible factor; IFN: Interferon; IgG: Immunoglobulin G; KDR: Kinase insert domain receptor; LDH: Lactate dehydrogenase; miRNA: messenger ribonucleic acid; PBS: Phosphate buffered saline; PDGF-AA: Platelet derived growth factor; PGF: Placental growth factor; pO2: Partial pressure of oxygen; P53: P53; RIPA: Radioimmunoprecipitation assay; RPMI: Roswell Park Memorial Institute; SEM: Standard error of the mean; SFM: Serum free medium; TNF: Tumour necrosis factor; VEGFR: Vascular endothelial growth factor receptor.

**Competing interests**

DOB, SJH and VLB are inventors on patents relating to VEGF-A165b. MHZ and PWS have no competing interests.

**Authors’ contributions**

VLB and MHZ carried out the cell biology assays. PSW and SJH participated in the design of the study. VLB and DOB analysed the results, conceived the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.
Acknowledgements

This work was supported by the British Heart Foundation (FS05/100 and 85/06/005). The authors have no interests to disclose. Experiments were conceived and designed by DOB, P5W, S/H and VLB, carried out by VLB and NH2, analysed by DOB, and VLB, and the manuscript was written by DOB and VLB. All authors commented on and contributed to the manuscript. Ethics approval was not required for this study.

Author details
1 Microvascular Research Laboratories, School of Physiology and Pharmacology, Veterinary Sciences Building, Southwell St, Bristol BS2 8EJ, UK.
2 Department of Obstetrics and Gynaecology, St Michael's Hospital, Bristol, UK.
3 Cancer Biology, Division of Oncology, University of Nottingham, Queen's Medical Centre, Nottingham NG2 7QT, UK.

Received: 20 November 2013 Accepted: 9 July 2014
Published: 15 August 2014

References

1. Redifer F, Simon P, Donner C, Jauniaux E: Oxygen measurements in endometrial and trophoblastic tissues during early pregnancy. Obstet Gynecol 1992, 80(2):283–285.
2. Jauniaux E, Watson A, Burton G: Endometrial base gradients in human fetal fluids and uteroplacental tissue between 7 and 16 weeks' gestation. Am J Obstet Gynecol 2001, 184(5):998–1003.
3. Gentbacev O, Zhou Y, Ludlow JW, Fisher SJ: Regulation of human placental development by oxygen tension. Science 1997, 277(5322):1669–1672.
4. Caniggia I, Mostastchi H, Winter J, Gassmann M, Lye SJ, Pulizewski M, Post M: Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFbeta(3). J Clin Invest 2000, 105(5):577–587.
5. Nadeem L, Munir S, Fu G, Dunc C, Baczuky D, Caniggia I, Lye S, Peng C: Nodal signals through activin receptor-like kinase 7 to inhibit trophoblast migration and invasion: implication in the pathogenesis of preeclampsia. Am J Pathol 2011, 178(3):1177–1189.
6. Clark DE, Smith SK, Sharkey AM, Charnock-Jones DS: Localization of VEGF and expression of its receptors flt and KDR in human placenta throughout pregnancy. Hum Reprod 1996, 11(5):1090–1098.
7. Harper SJ, Bates DO: VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer 2008, 8(1):88–97.
8. Ferrara N: Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004, 25(4):581–611.
9. Bates DO, Cui TG, Doughty JM, Winkler M, Sugimoto M, Shields JD, Peat D, Gillatt D, Harper SJ: VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res 2002, 62(14):4123–4131.
10. Cebe Suarez S, Pieren M, Cariolato L, Amos S, Hoffmann U, Bouchard A, Manulis C, Wood J, Balmer-Boyer K: A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2. Cell Mol Life Sci 2006, 63(17):2067–2077.
11. Bevan HS, van den Akker NA, Qu Y, Polman JA, Foster RR, Yemm J, Nishiikawa A, Sanchell SC, Harper SJ, Gittenberger-de Groot AC, Bates DO: The alternatively spliced anti-angiogenic family of VEGF isoforms VEGFxxxb in human kidney development. Nephron Physiol 2008, 110(4):57–67.
12. Magnussen AL, Rennel ES, Hua J, Bevan HS, Beazley Long N, Lehting C, Gammons M, Fliege J, Harper SJ, Agostini HT, Bates DO, Churchill AJ: Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to increased placental apoptosis in pregnancies complicated by preeclampsia. Am J Obstet Gynecol 2001, 184(6):1249–1250.
13. Whitely GS, Dash PR, Aylings L, Perumoo F, Thilagathan B, Cartwright JE: Increased apoptosis in first trimester extravillous trophoblasts from pregnancies at higher risk of developing preeclampsia. Am J Pathol 2007, 170(6):1903–1909.
14. Crocker IP, Tansinda DM, Baker PN: Altered cell kinetics in cultured placental villous explants in pregnancies complicated by pre-eclampsia and intrauterine growth restriction. J Pathol 2004, 204(1):11–18.
15. Perkins J, St John J, Ahmed A: Modulation of trophoblast cell death by oxygen and EGF. Mol Med 2002, 8(12):847–858.
16. Smith S, Francis R, Gilbert L, Baker PN: Growth factor rescue of cytokine mediated trophoblast apoptosis. Placenta 2002, 23(4):322–330.
17. Shore VH, Wang TH, Wang CL, Tony RJ, Caudle MR, Tony RS: Vascular endothelial growth factor, placenta growth factor and their receptors in isolated human trophoblast. Placenta 1997, 18(8):657–665.
18. Fitzpatrick TE, Lash GE, Yanahara A, Charnock-Jones DS, Macdonald-Goodfellow SK, Graham CH: Inhibition of breast carcinoma and trophoblast cell invasiveness by vascular endothelial growth factor. Exp Cell Res 2003, 283(2):247–255.
19. Aschenkien S, Straszewski S, Verwer KM, Foellmer H, Rutherford T, Mor G: Differential regulation and function of the Fas/Fas ligand system in human trophoblast cells. Biol Reprod 2002, 66(6):1853–1861.